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Abstract: Biocatalysis reproduce nature’s synthetic strategies in order to synthesize different organic
compounds. Natural metabolic pathways usually involve complex networks to support cellular
growth and survival. In this regard, multi-enzymatic systems are valuable tools for the production of
a wide variety of organic compounds. Methods: The production of different purine nucleosides and
nucleoside-5′-monophosphates has been performed for first time, catalyzed by the sequential action of
2′-deoxyribosyltransferase from Lactobacillus delbrueckii (LdNDT) and hypoxanthine-guanine-xanthine
phosphoribosyltransferase from Thermus themophilus HB8 (TtHGXPRT). Results: The biochemical
characterization of LdNDT reveals that the enzyme is active and stable in a broad range of
pH, temperature, and ionic strength. Substrate specificity studies showed a high promiscuity
in the recognition of purine analogues. Finally, the enzymatic production of different purine
derivatives was performed to evaluate the efficiency of multi-enzymatic system LdNDT/TtHGXPRT.
Conclusions: The production of different therapeutic purine nucleosides was efficiently catalyzed by
LdNDT/TtHGXPRT. In addition, the resulting by-products were converted to IMP and GMP. Taking
all of these features, this bioprocess entails an efficient, sustainable, and economical alternative to
chemical synthetic methods.
Keywords: 2′-deoxyribosyltransferase; phosphoribosyltransferases; cascade reactions; purine
nucleoside analogues; dietary nucleotides
1. Introduction
Nucleoside analogues, NAs, form a very large family of compounds, with more than 40 presently
used in medicine as antiviral and anticancer agents [1,2]. Actually, a variety of therapeutic nucleosides
and nucleotides, which are in the WHO “List of essential medicines” are produced chemically, such as
Abacavir (HIV therapeutic), Capecitabine (anticancer), Cytarabine (anticancer, antiviral), Vidarabine
(antiviral), or Floxuridine (anticancer), among others. Due to the economic and social relevance of
these kind of drugs, the availability of a stereo-selective and cheap synthetic method is relevant for the
industry and developing countries.
Furthermore, nucleoside-5′-monophosphates, NMPs, are often used as food additives or
intermediates by the pharmaceutical industry. For example, some dietary nucleotides, such as
inosinic acid (inosine-5′-monophosphate, IMP) or guanosinic acid (guanosine-5′-monophosphate,
GMP), are common additives used as flavour enhancers in foods, since they induce an umami taste
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sensation [3]. As a result, current demand for nucleotides in the food additives market is increasing,
and the production of nucleotides has been widely studied.
NAs and NMPs have been traditionally synthesized by chemical methods through multistep
processes requiring protection and de-protection steps for the labile groups, and isolation in almost
every step due to the poor regio- or stereoselectivity of the reactions [4–8]. These drawbacks lead to a
high price of these valuable compounds, limiting their application.
Nowadays, the application of bioprocesses that are catalyzed by whole cells or enzymes
in industry is gaining ground against traditional chemical synthetic processes. In this context,
the enzymatic synthesis of NAs and NMPs shows many advantages, such as one-pot reactions under
mild conditions, high stereo-, and regioselectivity, and an environmentally friendly technology [4–11].
Purine metabolism is a metabolic route of vital importance in all the living organisms, since
purines are essential for the synthesis of nucleic acids (DNA and RNA), proteins, and other metabolites.
In the de novo pathway cells use simple precursors like glycine, glutamine, or aspartate for the synthesis
of the different purine nucleotides. On the contrary, the salvage pathway is composed by a group of
reutilization routes by which the cell can satisfy its purine requirements from endogenous and/or
exogenous sources of preformed purines. In this regard, numerous enzymes from purine salvage
pathway have become valuable catalysts for mono or multi-enzymatic synthesis of nucleosides and
nucleotides, such as nucleoside kinases (NKs) [12–15], phosphoribosyltransferases [7,9–11], nucleoside
phosphorylases [4,8,16,17], 2′-deoxyribosyltransferases [5,18–20], among others.
The use of multi-enzymatic systems in organic synthesis offers several advantages, such
as the realization of more complex synthetic schemes, the ability to make reversible processes
irreversible, to shift the equilibrium reaction in desired way, and the partial or total elimination
of product inhibition problems or the prevention of the shortage of substrates by dilution or
degradation in the bulk media [13]. In this regard, the aim of this work is the development
of a novel multi-enzymatic system for the industrial production of different NAs and NMPs
with application in pharmaceutical and food industry. To achieve this objective, an in vitro
multienzymatic system composed by 2′-deoxyribosyltransferase from Lactobacillus delbrueckii (LdNDT)
and the hypoxanthine-guanine-xanthine phosphoribosyltransferase from Thermus themophilus HB8
(TtHGXPRT), is developed. As shown in Figure 1, the sequential action of LdNDT and
hypoxanthine-guanine-xanthine TtHGXPRT can efficiently catalyze the synthesis of NAs and NMPs in
two steps.
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Figure 1. Multi-enzymatic system LdNDT/TtHGXPRT. B1 and B2: Purine bases; dN: 
2′-deoxynucleoside; NMP: nucleoside-5′-monoposphate. 
Nucleoside 2′-deoxyribosyltransferases (NDTs, E.C. 2.4.2.6) catalyze the transglycosylation 
reaction between a 2′-deoxynucleoside donor and a nucleobase acceptor. According to their 
substrate specificity, NDTs can be classified into two classes: type I (PDT), specific for purines 
(Pur↔Pur), and type II (NDT), which catalyze the transfer between purines and/or pyrimidines 
(Pur↔Pur, Pur↔Pyr, Pyr↔Pyr) [5,19,20] (Figure 1). 
Figure 1. Multi-enzymatic system Ld T/TtHGXPRT. B1 and B2: Purine bases; d :
2′- eoxy cleosi e; : cleosi e-5′- o o os ate.
Nucleoside 2′-deoxyribosyltransferases (NDTs, E.C. 2.4.2.6) catalyze the transglycosylation
reaction between a 2′-deoxynucleoside donor and a nucleobase acceptor. According to their substrate
specificity, NDTs can be classified into two classes: type I (PDT), specific for purines (Pur↔Pur), and
type II (NDT), which catalyze the transfer between purines and/or pyrimidines (Pur↔Pur, Pur↔Pyr,
Pyr↔Pyr) [5,19,20] (Figure 1).
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Purine and pyrimidine phosphoribosyltransferases (PRTs) catalyze the reversible transfer of
the 5-phosphoribosyl group from 5-phospho-α-D-ribosyl-1-pyrophosphate (PRPP) to purine and
pyrimidine nucleobases or derivatives in the presence of Mg2+ (Figure 1).
The coupled system LdNDT/TtHGXPRT allowed for the enzymatic production of different
NAs by transglycosilation reaction using 2′-deoxynosine or 2′-deoxyguanosine as donors, and
different modified purine nucleobases as acceptors. Interestingly, TtHGXPRT can slightly shift the
equilibrium reaction of the NDT-catalyzed transglycosylation reaction in desired way, and partially
eliminate undesired by-products (hypoxanthine or guanine) from bulk-media using PRTs to synthesize
highly valuable nucleoside-5′-monophosphates (NMPs), commercially available as food additives
(IMP or GMP).
2. Results
2.1. Production, Purification and Substrate Specificity of Recombinant LdNDT
The ndt gene, encoding a 2′-deoxyribosyltransferase from Lactobacillus delbrueckii, was cloned and
over-expressed in E. coli BL21 (DE3), as described above. The recombinant N-terminal His6-tagged
LdNDT was purified using affinity chromatography. After this process, N-terminal His6-tagged
was removed from LdNDT using thrombin to avoid precipitation of the protein. To classify our
recombinant protein, we carried out the enzymatic synthesis of nucleosides using different ribo-
and 2′-deoxyribonucleosides as donors and several purine and pyrimidine bases as acceptors
(Table 1). In this regard, uridine (Uri), adenosine (Ado), cytdine (Cyd), 2′-deoxyadenosine (dAdo),
2′-deoxyuridine (dUri), 2′-deoxycytidine (dCyd), thymidine (dThd), 2′-deoxyinosine (dIno) and
2′-deoxyguanosine (dGuo) were tested as donors, and adenine (Ade), uracil (Ura), cytosine (Cyt),
thymine (Thy) and hypoxanthine (Hyp) were used as acceptors. LdNDT did not show any activity
on Uri, Cyd and Ado (data not shown). LdNDT is type II NDT, active over purine and pyrimidine
2′-deoxynucleosides and bases with a strong preference for dCyd and dUrd as best donors, followed
by Thd. In turn, the most and least preferred acceptors are Ade, Cyt and Ura.
Table 1. Substrate specificity of LdNDT upon synthesis of natural nucleosides.
Donor
Acceptor Specific Activity (IU/mg Protein)
Ade Ura Cyt Thy Hyp
dAdo – 43 ± 5 83 ± 8 45 ± 2 7.5 ± 1
dUrd 187 ± 2 – 165 ± 6 135 ± 5 106 ± 7
dCyd 189 ± 7 104 ± 6 – 48 ± 8 101 ± 8
Thd 101 ± 4 113 ± 3 113 ± 6 – 88 ± 8
dIno 22 ± 8 40 ± 4 64 ± 7 40 ± 0 –
dGua 116 ± 9 54 ± 4 80 ± 2 22 ± 4 20 ± 3
Reaction conditions: 0.3 µg of enzyme were incubated at 50 ◦C and and 300 rpm for 5 min with 10 mM substrates in
50 mM MES buffer, pH 6.5 in a final volume of 40 µL.
2.2. Biochemical Characterization of LdNDT
The effects of temperature, pH, and ionic strength on the stability and activity of the enzyme
were studied to determine the optimal operational conditions of the enzyme (Figure 2). The pH profile
revealed that LdNDT displays optimal activity in the pH range 6–7, with maximum activity in 50 mM
phosphate pH 6.0 (Figure 2a). As shown in Figure 2b, LdNDT displayed high activity (more than
60%) across a broad temperature range (from 40 ◦C to 70 ◦C), with the maximum activity at 60 ◦C.
In addition, a negligible loss of activity was observed in presence of 500 mM of sodium chloride, and a
slight activity decrease was observed when sodium chloride concentration was increased (60% activity
remained at 1 M sodium chloride) (Figure 2c).
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The storage of LdNDT at 4 ◦C was analyzed to ensure biocatalyst stability, and LdNDT retained
its activity more than 150 days (85% relative activity) (data not shown). LdNDT also displays 90% of
retained activity when is stored at −20 ◦C or −80 ◦C. In addition, the effect of pH on LdNDT stability
was evaluated by incubating the enzyme for 30 h at 50 ◦C at different pH conditions (ranging from
6.5 to 10). As we can see in Figure 2d, there was a negligible loss of activity in any case under these
experimental conditions.
2.3. Enzymatic Production of Purine NAs Catalyzed by LdNDT
In order to explore the potential of LdNDT as an industrial biocatalyst, the enzymatic
production of several nucleoside analogues was carried out using different non-n tural purine
bases under different assay conditions. As we can see in Table 2, LdNDT is able to recognize
many different purine analogues, such as 2-fluoroadenine (2-FAde), 2-chloroadenine (2-ClAde),
2,6-diaminourine (2,6-DAP), 6-chloropurine (6-ClPur), 6-mercaptopurine (6-M), 6-methylpurine
(6-Met) 6-methoxyguanine (6-MeOGua), 7-deaza-6-hydroxypurine (7-deaza6OHPur), 7-deazaxanthine
(7-deazaXan), theophylline (The) benzoyladenine (BenzoA), and xanthine (Xan).
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Table 2. Enzymatic productions of nucleoside analogues from purine base derivatives catalyzed by
LdNDT.
Donor Acceptor Product Conversion (%)
dIno
2-FAde 2-F-dAdo 64 ± 3
2-ClAde 2-CldAdo 34 ± 1
2,6-DAP 2,6-DAPdRib 81 ± 0
6-ClPur 6-ClPurdRib 70 ± 3
6-M 6-MdRib 9 ± 2
6-MetPur 6-MetPurdRib 51 ± 4
6-MeOGua 6-MeOdGuo 61 ± 3
7-deaza6OHPur 7-deaza6OHPurdRib 4 ± 0
7-deazaXan 7-deazadXao <1 ± 0.5
The ThedRib 17 ± 3
BenzoA BenzoAdRib 10 ± 2
Xan dXao 15 ± 3
Reaction conditions: 0.3 µg of enzyme in 40 µL at 50 ◦C and and 300 rpm, 20 min. [Substrates] = 1 mM, 50 mM
sodium phosphate buffer, pH 6.0.
2.4. Enzymatic Production of Purine NAs and Purine NMPs Catalyzed by Multi-Enzymatic System
LdNDT/TtHXGPRT
With the aim of evaluating an alternative methodology for the synthesis of purine NAs and NMPs,
the efficiency of multi-enzymatic system LdNDT/TtHXGPRT was tested. For this purpose, different
reactions were performed using dIno or dGuo as nucleoside donor in combination with different
purine derivatives as acceptors. After the transglycosilation reaction catalyzed by LdNDT (Reaction 1),
the resulting by-products (Hyp or Gua) were converted to IMP or GMP by TtHGXPRT (Reaction 2)
(Figure 1).
In order to evaluate the efficiency of this multi-enzymatic system against soluble LdNDT, the
synthesis of 2′deoxycytidine (dCyd) has been performed by two different approaches. On the one
hand, dCyd has been synthesized from 2′-deoxyguanosine (dGuo) and cytosine (Cyt) by LdNDT at
different substrate concentrations of donor (3 mM and 1 mM) and acceptor (1 mM) (Table S1). On
the other hand, dCyd was produced under similar conditions in presence of LdNDT/TtHXGPRT
(Table S1). As expected, the presence of TtHXGPRT leads to an improvement of conversion in
transglycosylation reaction (reaction 1), but there is no a great difference in nucleoside production in
presence of LdNDT/TtHXGPRT against soluble LdNDT. Interestingly, the ratio 3/1 (donor/acceptor)
seems to be the optimal molar ratio between donor and acceptor (Table S1). In addition, in order to
know if the presence of phosphate affects the reaction (high phosphate buffers can chelate Mg2+ and
decrease the concentration of Mg2+ in reaction medium), authors have tested the transferase reaction
(reaction 2) in presence of phosphate buffer and sodium borate buffer, with negligible difference in
activity (data not shown).
Taking account of the results, many different nucleoside analogues, such as
2-fluoro-2′-deoxyadenosine (2-F-dAdo), 2-chloro-2′-deoxyadenosine (cladribine, 2-CldAdo),
2,6-diaminopurine-2’-deoxyriboside (2,6-DAPdRib), 6-mercaptopurine-2’-deoxyriboside (6-MdRib),
6-methyl-2’-deoxyriboside (6-MetPurdRib), and 6-methoxy-2’-deoxyguanosine (6-MeOdGuo) have
been produced by employing this unprecedented multi-enzymatic system (Table 3).
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Table 3. Enzymatic production of nucleoside and nucleotide analogues from purine base derivatives
























































































































Reaction conditions: 0.3 µg of LdNDT, 1 µg of TtHGXPRT in 40 µL at 50 ◦C and 300 rpm, 20–60 min. [dIno] = [dGuo]
= 3 mM; [base] = 1 mM, [PRPP] = 1 mM, [MgCL2] = 1.2 mM, in 50 mM sodium phosphate buffer, pH 6.0.
3. Discussion
Nucleoside analogues are important molecules used as antiviral and antitumoral drugs [1,2,21],
because of their role as inhibitors of the replication of nucleic acids, and can also be employed as starting
materials for antisense oligonucleotides. Modified nucleosides have been traditionally synthesized by
different chemical methods, requiring the use of protection-deprotection steps, organic solvents and
chemical reagents [4–11]. In this sense, LdNDT has shown to be an interesting sustainable alternative
to traditional chemical methods for the synthesis of many different purine nucleosides. However,
the presence of by-products (nucleobases), or the difficulty to shift the equilibrium of the reaction
in desired way, increases production costs, impeding the scale up these processes from laboratory
to industry.
Cascades involving enzymes have recently become a thoroughly-investigated field, which
offers efficient solutions to circumvent these problems, by removing by-products and leading to
shift the reaction towards the formation of products. In this regard, the aim of this work is the
development of a new efficient coupled system, which consists in two consecutive reactions catalyzed
by LdNDT (Reaction 1) and TtHGXPRT (Reaction 2), which leads to: (i) a more efficient production of
2′-deoxynucleoside analogues due to the shift of the equilibrium of transglycosylation reaction, and
(ii) the generation of NMPs with application in food industry.
For this purpose, we describe the production and biochemical characterization of
2′-deoxyribosyltransferase from LdNDT. According substrate specificity studies, LdNDT is a type
II NDT, which recognizes both purine and pyrimidine bases and 2’-deoxynucleosides. LdNDT present
significant catalytic activity in a broad temperature range (from 40 ◦C to 70 ◦C) (Figure 2b) and displays
its optimal activity in the pH range 6–7 (Figure 2a). According to experimental results, LdNDT is also
stable between pH 6–10 at 50 ◦C. These results suggest that alkaline environments (pH 8–10) could not
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inactivate the enzyme during this time period (Figure 2d). In order to explore the potential of LdNDT
as biocatalyst, the enzymatic production of different purine 2′-deoxynucleoside analogues has been
carried out.
Once operational conditions of LdNDT were determined, a multienzymatic system
composed by 2′-deoxyribosyltransferase from Lactobacillus delbrueckii (LdNDT) and the
hypoxanthine-guanine-xanthine phosphoribosyltransferase from Thermus themophilus HB8
(TtHGXPRT) were developed. The use of coupled system LdNDT/TtHGXPRT allowed for the
synthesis of different therapeutical purine nucleosides, such as 2-chloro-2′-deoxyadenosine (cladribine,
approved FDA drug for the treatment of hairy-cell leukemia [1], 2-fluro-2′-deoxyadenosine (a prodrug
of 2-fluoroadenine, used in suicide gene therapy [1]), among others. In addition, resulting by-products
from transglycosylation reaction (hypoxanthine or guanine) were transformed to added value
compounds (IMP or GMP). Moreover, due to TtHXGPRT is a 6-oxopurine phosphoribosyltransferase
(with a strict specificity for 6-oxopurines, such as guanine and hypoxanthine [11]), the purine base
derivatives used as acceptors in transglycosylation reaction (B2) (Figure 1) cannot be recognized by
TtHXGPRT. As a consequence of this, there will not undesired by-products in reaction medium.
In addition to this, the unusual tolerance to alkaline conditions of LdNDT and TtHGXPRT [11],
it is a very interesting advantage for covalent immobilization of the enzyme, an essential requisite
for its industrial implementation. Covalent immobilization of proteins usually occurs via multipoint
attachment through the region with higher density of primary amino groups, especially with ε-NH2
from lysine residues [22]. Due to this, covalent immobilization techniques usually employ long
reaction times (2–24 h) and alkaline conditions (pH 8–10). In this way, the exceptional stability that
is displayed by LdNDT and TtHGXPRT [11] under alkaline conditions suggests that they could be
efficiently immobilized.
However, this multienzymatic approach needs to improve several features in order to be applied
as industrial biocatalyst, such as the possibility to shift totally the equilibrium or the high price of PRPP.
One of the most significant limitations to the practical application of this multi-enzymatic system
as industrial biocatalysts is the high cost and instability of PRPP. To address these issues, several
attempts to produce PRPP from non-expensive substrates will tested in a future including different
PRPP sources. In addition, high concentrations of PRPP and phosphate, buffer would chelate Mg2+
from reaction medium, and affect the efficiency of TtHGXPRT. In this sense, in order to scale up this
process, the conversion of reaction 2 could be improved using higher concentrations of MgCl2.
4. Materials and Methods
4.1. Chemicals
Cell culture medium reagents were from Difco (St. Louis, MO, USA). Trimethyl ammonium
acetate buffer was purchased from Sigma-Aldrich (Sigma-Aldrich, Madrid, Spain). All the other
reagents and organic solvents were purchased to Scharlab (Scharlab, Barcelona, Spain) and Symta
(Symta, Madrid, Spain). All natural and non-natural nucleosides and bases used in this work were
provided by Carbosynth Ltd. (Carbosynth Ltd., Compton, UK).
4.2. Production and Purification of Recombinant LdNDT and TtHGXPRT
The encoding ndt gene, which codifies 2′-deoxyribosyltransferase type II from Lactobacillus
delbrueckii subsp. lactis DSM 20072 (NCBI Reference Sequence: WP_002877839.1) was ordered and
purchased from Genscript (Piscataway, NJ, USA). The coding sequence appeared as an NdeI-EcorI
fragment was subcloned into the expression vector pET28b (+). The resultant, recombinant vector
pET28bLdNDT provided an N-terminal His6-tagged fusion protein with a thrombin cleavage site
between the tag and the enzyme. LdNDT was expressed in E. coli BL21(DE3) and growth in LB
medium at 37 ◦C with kanamycin 50 µg/mL. Protein overexpression was induced by adding 0.5 mM
isopropyl-β-D-1-thiogalactopyranoside and the cells were further grown for 3 h. These were harvested
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via centrifugation at 3500× g. The resulting pellet was resuspended in 10 mM sodium phosphate
buffer, pH 7.0. Crude extracts were prepared by French press lysis of cell suspensions. The lysate was
centrifuged at 17,500× g for 40 min and the supernatant was filtered through a 0.22 µm filter (Millipore).
Cleared lysate was loaded onto a 5-mL HisTrap FF column (GE Healthcare) pre-equilibrated in a
binding buffer (10 mM sodium phosphate buffer, pH 7.0, with 100 mM NaCl, and 10 mM imidazole)
and the column was washed. Bound proteins were eluted using a linear gradient of imidazole
(from 10 mM to 500 mM). After this process, fractions containing His6-tagged-LdNDT were pooled
and concentrated, and N-terminal His6-tagged was removed from LdNDT using thrombin to avoid
precipitation of the protein. In a second step, fractions containing LdNDT were loaded onto a HiLoad
16/60 Superdex 200 prep grade column (GE Healthcare) pre-equilibrated in 25 mM sodium phosphate
buffer, pH 7.0. Fractions with the protein of interest identified by SDS-PAGE were pooled and the
protein was dialyzed against 10 mM sodium phosphate, pH 6.0, and concentrated and stored at 4 ◦C,
until its use. Electrophoresis was carried out on 15% polyacrylamide slab gel with 25 mM Tris-HCl
buffer, pH 8.6, 0.1% SDS [23]. Protein concentration was determined spectrophotometrically by UV
absorption at 280 nm using ε280 = 34,380 M−1cm−1 [24].
TtHGXPRT was produced and purified according to experimental protocols, as previously
reported [11].
4.3. N-deoxyribosyltransferase Assay
The standard activity assay was performed by incubating 0.3 µg of pure enzyme with 10 mM
2′-deoxyinosine (dIno) and 10 mM adenine (Ade) in 50 mM MES buffer pH 6.0 in a final volume of
40 µL. The reaction mixture was incubated at 40 ◦C for 10 min (300 rpm). Enzyme was inactivated
by adding 40 µL of cold methanol in ice-bath and heating for 5 min at 100 ◦C. After centrifugation
at 9000× g for 2 min, the samples were half-diluted with water and frozen at −20 ◦C. Nucleoside
production was analysed using HPLC to measure quantitatively the reaction products, as described
below. All of the determinations were carried out in triplicate and the maximum error was less than
5%. Under such conditions, one international activity unit (IU) was defined as the amount of enzyme
producing 1 µmol/min of 2′-deoxyadenosine under the assay conditions.
4.4. Substrate Specificity
In order to explore the substrate specificity, 0.3 µg of LdNDT were incubated with 10 mM of
purine and pyrimidine nucleosides and bases in 50 mM MES buffer, pH 6.5 in a final volume of 40 µL
at 50 ◦C, and 300 rpm orbital shaking at different reaction times. At regular times, samples were taken,
and enzymatic activity was evaluated, as described in analytical methods section.
4.5. Influence of pH, Temperature and Ionic Strength on Enzyme Activity
The pH profile of purified recombinant enzyme was initially determined using the standard
assay described above with sodium citrate (pH 4–6), sodium phosphate (pH 6–8). MES (6–7) and
sodium borate (pH 8–10) as reaction buffers (50 mM). The optimum temperature was determined
using the standard assay across a 20–90 ◦C temperature range. The effect of ionic strength on
2′-deoxyribosyltransferase activity was studied by incubating 0.3 µg of enzyme with different
concentrations of NaCl (0 to 1.0 M) in 50 mM MES buffer, pH 6.0 at 50 ◦C under standard conditions
described for enzymatic assay.
4.6. Thermal and pH Stability of LdNDT
LdNDT was stored at −80 ◦C in 10 mM sodium phosphate, pH 7.0 for 300 days. Samples were
taken periodically and enzymatic activity was evaluated. Storage stability was defined as the relative
activity between the first and successive reactions. Moreover, thermal stability of LdNDT was assessed
by incubating 0.3 µg of pure enzyme in a pH range from 6 to 10, at 50 ◦C for a period of 30 h. After
this, the activity was measured using standard assay.
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4.7. Enzymatic Production of Nucleoside Analogues by Soluble LdNDT
Enzymatic productions of non-natural nucleosides was carried out at variable amounts of enzyme,
using different nucleoside and base analogues. Reactions were carried out incubating 0.3 µg of LdNDT
with 1 mM nucleoside and base, in 50 mM sodium phosphate buffer pH 6.0 at 50 ◦C, in a final volume
of 40 µL, with 300 rpm orbital shaking at different reaction times (20–120 min), and were stopped
according experimental procedure described above. Enzymatic activity was evaluated, as described in
analytical methods section.
4.8. Enzymatic Production of Purine NAs and Purine NMPs Catalyzed by Multi-Enzymatic System
LdNDT/TtHGXPRT
Reaction mixtures contained 0.3 µg of electrophoretically pure LdNDT, 1 µg of TtHGXPRT, 3 mM
2′-deoxynucleoside, 1 mM nucleobase, 1 mM 5-phospho-α-D-ribosyl-1-pyrophosphate (5-PRPP) and
1.2 mM MgCl2 in 50 mM sodium phosphate buffer, pH 6.0, in a final volume of 40 µL. Reactions were
conducted at 50 ◦C with shaking (300 rpm) at different reaction times (20–120 min), and were stopped
according experimental procedure described above. Enzymatic activity was evaluated, as described in
analytical methods section.
4.9. Analytical Methods
4.9.1. Analytical Methods for LdNDT
The production of nucleosides was quantitatively measured with an ACE 5 µm C18-PFP column
250 mm × 46 mm (Symta, Madrid, Spain) pre-equilibrated in 100% trimethyl ammonium acetate.
Elution was carried out at a flow rate of 0.9 mL/min, by a discontinuous gradient: 0–10 min, 100% to
90% trimethyl ammonium acetate and 0% to 10% acetonitrile, and 10–20 min, 90% to 100% trimethyl
ammonium acetate and 10% to 0% acetonitrile. The nucleoside product was eluted into the diode array
detector for quantification at 230, 240, 254, and 260 nm.
Retention times for the reference natural and non-natural bases (hereafter abbreviated according
to the recommendations of the IUPAC-IUB Commission on Biochemical Nomenclature) were
as follows: adenine (Ade), 10.2 min; guanine (Gua), 7.3 min; hypoxanthine (Hyp), 7.5 min;
benzimidazole (B), 29.6 min; 2,6-diaminopurine (2,6-DAP), 11.1 min; 6-mercaptopurine (6-M),
10.5 min; 6-methylpurine (6-MetPur): 13.8 min; 2-fluoroadenine (2-FAde), 14.4 min; 6-benzoyladenine
(6-BenzoAde), 16.6; 2-chloroadenine (2-ClAde), 17.3 min; 6-chloropurine (6-ClPur), 16.7 min;
6-methoxyguanine (6-MeOGua), 16.4 min; 7-deaza-6-hydroxypurine (7-deaza6OHPur), 9.0 min;
7-deazaxanthine (7-deazaXan), 8.5 min; theophylline (The), 20.0 min; benzoyladenine (BenzoA);
22 min; and, xanthine (Xan), 8 min.
Retention times for the nucleosides (hereafter abbreviated according to the
recommendations of the IUPAC-IUB Commission on Biochemical Nomenclature) were
as follows: 2′-deoxyadenosine (dAdo), 15.5 min; 2′-deoxyguanosine (dGuo), 11.6 min;
2′-deoxyinosine (dIno), 12.0 min; 33.5; 2,6-diaminopurine-2′-deoxyribose (2,6-DAPdRib), 16.0 min;
6-mercaptopurine-2′-deoxyribose (6-MdRib), 13.5 min; 6-methylpurine-2′-deoxyribose (6-MetPurdRib),
17.7 min; 2-fluoro-2′-deoxyadenosine (2-F-dAdo), 19.0 min, 2-chloro-2′-deoxyadenosine (2-CldAdo),
23.2 min; 6-chloropurine-2′-deoxyribose (6-ClPurdRib), 22.9 min; 6-methoxy-2′-deoxyguanosine
(6-MeOdGuo), 21.8 min; 7-deaza-6-hydroxypurine-2’-deoxyribose (7-deaza6OHPurdRib), 14.0 min;
7-deazaxanthine-2′-deoxyribose (7-deazadXao), 13.5 min; theophylline-2′-deoxyribose (ThedRib),
27.0 min; benzoyladenine-2’-deoxyribose (BenzoAdRib); 29.0 min; and, 2′-deoxyxanthosine (dXao),
13.0 min. The identification and quantification of most of reaction substrates and products have
been performed in relation to external standards using the above, well characterized commercial
products. In the case of 7-deaza-6-hydroxypurine-2′-deoxyribose, 7-deazaxanthine-2′-deoxyribose,
theophylline-2′-deoxyribose, and benzoyladenine-2′-deoxyribose we use the decrease of corresponding
starting nucleobases to quantify the formation of products.
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4.9.2. Analytical Methods for Multi-Enzymatic System LdNDT/TtHGXPRT
The production of 2′-deoxynucleosides and nucleoside-5′-monophosphates was quantitatively
measured with an ACE EXCEL 5 µm CN-ES column 250 mm × 4.6 mm (Symta, Madrid, Spain)
equilibrated with 100% trimethyl ammonium acetate at a flow rate of 0.8 mL/min. The nucleoside
product was eluted into the diode array detector for quantification at 230, 240, 254, and 260 nm.
Retention times for the reference natural and non-natural bases (hereafter abbreviated according to
the recommendations of the IUPAC-IUB Commission on Biochemical Nomenclature) were as follows:
adenine (Ade), 10.2 min; guanine (Gua), 5.8 min; hypoxanthine (Hyp), 5.3 min; 2,6-diaminopurine
(2,6-DAP), 9.5 min; 6-mercaptopurine (6-M), 7.8 min; 6-methylpurine (6-MetPur): 14.5 min;
2-fluoroadenine (2-FAde), 14.4 min; 2-chloroadenine (2-ClAde), 25.0 min; and, 6-methoxyguanine
(6-MeOGua), 19.4 min.
Retention times for the nucleosides (hereafter abbreviated according to the
recommendations of the IUPAC-IUB Commission on Biochemical Nomenclature) were
as follows: 2′-deoxyadenosine (dAdo), 19.5 min; 2′-deoxyguanosine (dGuo), 10.2 min;
2′-deoxyinosine (dIno), 9.0 min; 33.5; 2,6-diaminopurine-2’-deoxyribose (2,6-DAPdRib), 20.1 min;
6-mercaptopurine-2′-deoxyribose (6-MdRib), 11.5 min; 6-methylpurine-2′-deoxyribose (6-MetPurdRib),
33.4 min; 2-fluoro-2′-deoxyadenosine (2-F-dAdo), 34.0 min, 2-chloro-2′-deoxyadenosine (2-CldAdo),
65.0 min; and, 6-methoxy-2′-deoxyguanosine (6-MeOdGuo), 27.8 min.
Retention times for the nucleosides-5’-monophosphate (hereafter abbreviated according to the
recommendations of the IUPAC-IUB Commission on Biochemical Nomenclature) were as follows:
guanosine-5′-monophosphate (5′-GMP), 3.1 min; inosine-5′- monophosphate (5′-IMP), 3.4 min.
The identification and quantification of most of reaction substrates and products have been
performed in relation to external standards using the above, well characterized commercial products.
5. Conclusions
In conclusion, the use of multi-enzymatic system LdNDT/TtHGXPRT for the synthesis of purine
NAs and purine NMPs could be a very interesting methodology for industrial synthesis of nucleic
acid derivatives. In addition, the use of LdNDT/TtHGXPRT would offer the possibility to transform
resulting by-products in high-value compounds and shift the equilibrium reaction of transglycosylation
reaction in desired way. Despite several drawbacks need to be improved, such as the high price of
PRPP, the total displacement of reaction equilibrium, or the costs of the purification of NMPS and NAs,
the high price of some of these therapeutic nucleosides, and the sustainability of this process are good
reasons to deepen into this novel bioprocess.
Supplementary Materials: The following are available online at www.mdpi.com/2073-4344/8/1/9/s1, Table S1:
Effect of molar ratio in the production of purine NAs catalyzed by LdNDT or LdNDT/TtHGXPRT.
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